Possible therapeutic options and management of COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/28002 |
Resumo: | Currently, there is no effective therapy against Coronavirus disease 2019 (COVID-19). Thus, there is crucial requirement for effective therapy against COVID-19. To our knowledge, few investigations have been conducted on AT2 progenitor cells as target for the (SARS-CoV-2). Hence, alveolar type 2 progenitor cells may be a possible therapeutic agent against COVID19. This review focused on the pathogenesis and pathophysiology of COVID19 disease on AT2 cells and explored potential mechanisms to prevent infection and death of AT2 progenitor cells as possible therapy against COVID-19. We propose that inhibition of IL-1 receptor, IL 1, NFkB and JNK signalling pathway may serve as therapeutic target for COVID-19 |
id |
UNIFEI_75d7990942e80b3c968ae0c296b5f4ac |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/28002 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Possible therapeutic options and management of COVID-19Posibles opciones terapéuticas y manejo de la COVID-19Possíveis opções terapêuticas e gestão da COVID-19COVID-19Alveolar type 2PathogenesisTherapeutic.COVID-19Alveolar tipo 2PatogêneseTerapêutica.COVID-19Alveolar tipo 2PatogeniaTerapéutica.Currently, there is no effective therapy against Coronavirus disease 2019 (COVID-19). Thus, there is crucial requirement for effective therapy against COVID-19. To our knowledge, few investigations have been conducted on AT2 progenitor cells as target for the (SARS-CoV-2). Hence, alveolar type 2 progenitor cells may be a possible therapeutic agent against COVID19. This review focused on the pathogenesis and pathophysiology of COVID19 disease on AT2 cells and explored potential mechanisms to prevent infection and death of AT2 progenitor cells as possible therapy against COVID-19. We propose that inhibition of IL-1 receptor, IL 1, NFkB and JNK signalling pathway may serve as therapeutic target for COVID-19Actualmente, no existe una terapia efectiva contra la enfermedad por coronavirus 2019 (COVID-19). Por lo tanto, existe un requisito crucial para una terapia eficaz contra COVID-19. Hasta donde sabemos, se han realizado pocas investigaciones sobre las células progenitoras AT2 como objetivo para el (SARS-CoV-2). Por lo tanto, las células progenitoras alveolares tipo 2 pueden ser un posible agente terapéutico contra COVID19. Esta revisión se centró en la patogenia y la fisiopatología de la enfermedad COVID19 en las células AT2 y exploró los posibles mecanismos para prevenir la infección y la muerte de las células progenitoras AT2 como posible terapia contra la COVID-19. Proponemos que la inhibición de la vía de señalización del receptor IL-1, IL 1, NFkB y JNK puede servir como diana terapéutica para COVID-19.Atualmente, não existe uma terapia eficaz contra a doença de Coronavírus 2019 (COVID-19). Assim, há um requisito crucial para uma terapia eficaz contra o COVID-19. Até onde sabemos, poucas investigações foram conduzidas em células progenitoras AT2 como alvo para o (SARS-CoV-2). Assim, as células progenitoras alveolares tipo 2 podem ser um possível agente terapêutico contra o COVID19. Esta revisão se concentrou na patogênese e fisiopatologia da doença COVID19 em células AT2 e explorou mecanismos potenciais para prevenir a infecção e morte de células progenitoras AT2 como possível terapia contra COVID-19. Propomos que a inibição da via de sinalização do receptor de IL-1, IL 1, NFkB e JNK pode servir como alvo terapêutico para COVID-19.Research, Society and Development2022-04-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2800210.33448/rsd-v11i5.28002Research, Society and Development; Vol. 11 No. 5; e47711528002Research, Society and Development; Vol. 11 Núm. 5; e47711528002Research, Society and Development; v. 11 n. 5; e477115280022525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/28002/24783Copyright (c) 2022 Olajuyin Ayobami Matthew; Olajuyin Adefunke Kafayat; Adegoke Ayodeji Mathias; Jamiyu Ayodeji Saliu; Raji Muhammed Hayatu; Okeke Ifeanyi Malachy; Zhang Xiaojuhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAyobami Matthew, Olajuyin Adefunke Kafayat, Olajuyin Ayodeji Mathias, AdegokeSaliu, Jamiyu Ayodeji Hayatu, Raji Muhammed Malachy, Okeke Ifeanyi Xiaoju, Zhang 2022-04-17T18:18:56Zoai:ojs.pkp.sfu.ca:article/28002Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:33.610527Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Possible therapeutic options and management of COVID-19 Posibles opciones terapéuticas y manejo de la COVID-19 Possíveis opções terapêuticas e gestão da COVID-19 |
title |
Possible therapeutic options and management of COVID-19 |
spellingShingle |
Possible therapeutic options and management of COVID-19 Ayobami Matthew, Olajuyin COVID-19 Alveolar type 2 Pathogenesis Therapeutic. COVID-19 Alveolar tipo 2 Patogênese Terapêutica. COVID-19 Alveolar tipo 2 Patogenia Terapéutica. |
title_short |
Possible therapeutic options and management of COVID-19 |
title_full |
Possible therapeutic options and management of COVID-19 |
title_fullStr |
Possible therapeutic options and management of COVID-19 |
title_full_unstemmed |
Possible therapeutic options and management of COVID-19 |
title_sort |
Possible therapeutic options and management of COVID-19 |
author |
Ayobami Matthew, Olajuyin |
author_facet |
Ayobami Matthew, Olajuyin Adefunke Kafayat, Olajuyin Ayodeji Mathias, Adegoke Saliu, Jamiyu Ayodeji Hayatu, Raji Muhammed Malachy, Okeke Ifeanyi Xiaoju, Zhang |
author_role |
author |
author2 |
Adefunke Kafayat, Olajuyin Ayodeji Mathias, Adegoke Saliu, Jamiyu Ayodeji Hayatu, Raji Muhammed Malachy, Okeke Ifeanyi Xiaoju, Zhang |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Ayobami Matthew, Olajuyin Adefunke Kafayat, Olajuyin Ayodeji Mathias, Adegoke Saliu, Jamiyu Ayodeji Hayatu, Raji Muhammed Malachy, Okeke Ifeanyi Xiaoju, Zhang |
dc.subject.por.fl_str_mv |
COVID-19 Alveolar type 2 Pathogenesis Therapeutic. COVID-19 Alveolar tipo 2 Patogênese Terapêutica. COVID-19 Alveolar tipo 2 Patogenia Terapéutica. |
topic |
COVID-19 Alveolar type 2 Pathogenesis Therapeutic. COVID-19 Alveolar tipo 2 Patogênese Terapêutica. COVID-19 Alveolar tipo 2 Patogenia Terapéutica. |
description |
Currently, there is no effective therapy against Coronavirus disease 2019 (COVID-19). Thus, there is crucial requirement for effective therapy against COVID-19. To our knowledge, few investigations have been conducted on AT2 progenitor cells as target for the (SARS-CoV-2). Hence, alveolar type 2 progenitor cells may be a possible therapeutic agent against COVID19. This review focused on the pathogenesis and pathophysiology of COVID19 disease on AT2 cells and explored potential mechanisms to prevent infection and death of AT2 progenitor cells as possible therapy against COVID-19. We propose that inhibition of IL-1 receptor, IL 1, NFkB and JNK signalling pathway may serve as therapeutic target for COVID-19 |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04-14 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/28002 10.33448/rsd-v11i5.28002 |
url |
https://rsdjournal.org/index.php/rsd/article/view/28002 |
identifier_str_mv |
10.33448/rsd-v11i5.28002 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/28002/24783 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 5; e47711528002 Research, Society and Development; Vol. 11 Núm. 5; e47711528002 Research, Society and Development; v. 11 n. 5; e47711528002 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052794021085184 |